Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Genetically Encoded Engineering Switchable Circular RNA Devices for Targeted Protein Degradation.

Created on 17 Nov 2026

Authors

Shijia Zhou, Yang Xiao, Qiyong Hu, Bin Li, Shengyuan Deng, Xu He, Kewei Ren

Published in

Small (Weinheim an der Bergstrasse, Germany). Nov 17, 2026. Epub Nov 17, 2026.

Abstract

Targeted protein degradation has shown powerful capability for diseases treatment. However, the approach is limited by the challenges in cellular internalization of synthetic degrader and potential cytotoxicity. Herein, we propose a Genetically encoded circular RNA Aptamer-based DEgrader (GRADE) to control target proteins degradation. The GRADE system is facilely constructed by integrating a transferrin receptor (TfR1) aptamer and target protein aptamer for delivering target protein into damaged endosomes and TfR1 binding, leading to target protein degradation via endosomal autophagy pathways. We show that the versatile and modular GRADE could be applied to eliminate several intracellular target proteins. Moreover, the GRADE system can be selectively activated by endogenous biomarkers for achieving highly specific protein degradation and cancer cell precise inhibition. This study presents a non-invasive, effective and general platform for intracellular protein degradation, offering new insights into controlled cell manipulation and diseases therapy.

PMID:
43042720
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement